重症筋無力症治療市場の2030年までの予測：タイプ別、薬剤クラス別、治療モダリティ別、流通チャネル別、地域別の世界分析

Stratistics MRCによると、重症筋無力症治療の世界市場は2023年に22億米ドルを占め、予測期間中にCAGR 8.5％で成長し、2030年には39億米ドルに達すると予測されています。

重症筋無力症（MG）治療市場は、筋力低下と疲労を特徴とする慢性的な自己免疫性神経筋疾患である重症筋無力症への対処に焦点を当てた医薬品および治療状況を指します。この市場には、症状の管理、神経筋伝達の改善、および重症筋無力症患者の全体的なQOLの向上を目的とした様々な医療介入が含まれます。

全米希少疾患機構（NORD）によると、米国では10万人あたり約14～40人が重症筋無力症に罹患しています。報告によると、重症筋無力症の頻度はここ数十年増加傾向にあります。これは、患者の特定が容易になったことと、世界中で自己免疫疾患の有病率が増加していることに起因しています。

医薬品の承認とパイプラインの開発

重症筋無力症（MG）の治療は、パイプラインの進展と薬剤承認によって大きく左右されます。新薬の承認は、より多くの治療選択肢を提供し、市場のギャップを埋め、患者の転帰を改善します。現在進行中のパイプラインの開発により、薬剤メカニズムの進歩や有効性の向上が期待され、治療方法の改善に専念していることが示されています。さらに、これらの開発により、MG患者に対する個別化された重点的な治療計画が実現され、副作用が軽減され、管理が改善される可能性があります。

疾患修飾療法の欠如

自己免疫疾患の複雑で多因子にわたる性質に関して、重症筋無力症（MG）の治療に利用可能な疾患修飾療法は現在のところ存在しないです。他の自己免疫疾患と異なり、重症筋無力症を引き起こす根本的な機序が完全には解明されていないため、標的療法の開発は困難です。現在の治療法の大半は、アセチルコリンエステラーゼ阻害剤と免疫抑制剤を用いて症状を管理するもので、症状を緩和するものであるが、根本的な原因には対処していないです。しかし、MGの根底にある正確なメカニズムや疾患修飾治療法の開発については、まだ多くのことが解明されているにもかかわらず、この疾患の複雑性が大きな障壁であり続けている。

併用療法

併用療法は、重症筋無力症（MG）の様々な側面に対処することで、有望な治療法となります。アセチルコリンエステラーゼ阻害剤と、コルチコステロイドや免疫調節剤などの免疫抑制剤は、MGの特徴である筋力低下と自己免疫反応を管理するために協調して作用します。さらに、特定の免疫経路を標的とする新規の生物学的療法は、従来の医療介入と併用できる可能性があります。併用療法は、複雑な病態生理学の異なる側面に対処することで、個々の薬剤の大量投与に関連する副作用を軽減しながら、効果を最大化することを目指します。

患者の反応のばらつき

重症筋無力症患者は複雑な自己免疫疾患であり、治療に対する反応は個人差があります。治療成績は、併存疾患、疾患の重症度、遺伝的変異を含む多くの要因によって異なります。この問題に対処するため、患者固有の特性に基づいて治療法をカスタマイズすることを目的とした精密医療のアプローチが研究されています。しかし、製薬企業や医療専門家は、MG患者の反応に固有のばらつきがあることを懸念し続けており、これは、市場で入手可能な治療介入の標準化と最適化に影響を及ぼしています。

COVID-19の影響：

ヘルスケアサービスやサプライチェーンにおける大きな混乱は、患者の医薬品へのアクセスに影響を及ぼしており、COVID-19は重症筋無力症（MG）治療市場における主要な要因となっています。遠隔医療は新たな診察の選択肢を広げたが、血漿交換や免疫グロブリン静注（IVIG）のような対面治療は物流上の困難に直面しています。さらに、パンデミックの経済的負担は、患者の経済的余裕とヘルスケア予算に影響を及ぼし、MG治療の市場にも影響を及ぼしています。このような困難に立ち向かいつつも、現在進行中の研究開発イニシアチブでは、現在の障害と将来の潜在的な市場力学の両方に対処する新規のMG治療法の研究が続けられています。

予測期間中、コリンエステラーゼ阻害剤セグメントが最大となる見込み

重症筋無力症治療薬市場は、自己免疫性神経筋疾患の症状治療に有効であることから、コリンエステラーゼ阻害薬分野で力強い成長を遂げています。アセチルコリンの分解を阻止することで、ピリドスチグミンのようなコリンエステラーゼ阻害薬は神経筋伝達を改善し、その結果、筋力と機能を向上させるのに不可欠です。さらに、重症筋無力症の治療法が変化し、包括的な治療計画にコリンエステラーゼ阻害薬を含めるヘルスケアプロバイダーが増えるにつれて、市場は拡大し続けると予想されます。

予測期間中、最もCAGRが高いと予想されるのは静脈内投与療法セグメントです。

重症筋無力症の急性症状を速やかに緩和する点から、静脈内療法（IVT）は重症筋無力症治療市場において成長分野となっています。重症筋無力症の増悪を治療する場合、静脈内投与は正確な投与量管理と静脈内免疫グロブリン（IVIG）のような免疫抑制剤の迅速なデリバリーを可能にします。重症例では、患者を安定させるための迅速な対応が保証されるため、この治療法は特に有用です。さらに、在宅IVTの利便性と注入技術の向上は、患者により便利で利用しやすい治療選択肢を提供することでこの市場セグメントの成長を支え、ひいては市場拡大を後押ししています。

最もシェアの高い地域

重症筋無力症（MG）治療薬の売上は、MG有病率の上昇、ヘルスケア施設の改善、疾患に対する一般市民の意識の高まりにより、アジア太平洋地域で大幅に増加しています。同地域における研究開発活動の活発化により、新たな治療オプションが導入されています。また、医療費の負担軽減と医療へのアクセスを改善するための政府プログラムも、市場の拡大を促進する上で不可欠です。さらに、重症筋無力症の治療状況は常に変化しており、APAC地域は個別化医療とバイオテクノロジーの進歩に重点を置くようになり、この進化に大きく貢献しています。

CAGRが最も高い地域：

欧州の重症筋無力症治療市場は、新しい治療法の導入、認知度の向上、医学研究の改善により、常に成長を続けています。治療の選択肢の拡大は、製薬企業とヘルスケア機関の提携によって促進されています。さらに、この地域の患者意識の高まりとヘルスケアインフラの改善が、重症筋無力症治療市場の拡大を後押ししています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレイヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の重症筋無力症治療市場：タイプ別

• 全身性重症筋無力症
• 重症筋無力症眼科
• 一過性新生児重症筋無力症
• その他のタイプ

第6章 世界の重症筋無力症治療市場：薬剤クラス別

• コリンエステラーゼ阻害剤
• モノクローナル抗体
• コルチコステロイド
• 免疫抑制剤
• 静脈内免疫グロブリン
• その他の薬物クラス

第7章 世界の重症筋無力症治療市場：治療モダリティ別

• 手術
• 点滴療法
• その他の治療モダリティ

第8章 世界の重症筋無力症治療市場：流通チャネル別

• オンライン薬局
• 病院薬局
• 小売薬局
• その他の流通チャネル

第9章 世界の重症筋無力症治療市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第10章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新薬クラスの発売
• 事業拡大
• その他の主要戦略

第11章 企業プロファイル

• AbbVie Inc.
• Alexion Pharmaceutical Inc.
• Amyasthenia gravisen inc.
• Astellas pharma inc.
• Astrazeneca
• Avadel Pharmaceuticals plc
• Bausch Health Companies Inc.
• Baxter International, Inc.
• Bayer ag
• Biogen
• Bristol-myers squibb
• CSL Behring
• Daiichi sankyo co. Ltd.
• F. Hoffmann-La Roche Ltd.
• Gilead sciences inc.
• Glaxosmithkline plc.
• Grifols SA
• Merck & co. Inc.
• Novartis AG
• Pfizer, Inc.
• Sanofi
• Servier laboratories
• Shire plc
• Takeda Pharmaceutical Company Limited
• Teva pharmaceutical industries ltd.
• Valeant Pharmaceuticals International, Inc.

List of Tables

• Table 1 Global Myasthenia Gravis Disease Treatment Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Myasthenia Gravis Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 3 Global Myasthenia Gravis Disease Treatment Market Outlook, By Generalized Myasthenia Gravis (2021-2030) ($MN)
• Table 4 Global Myasthenia Gravis Disease Treatment Market Outlook, By Ocular Myasthenia Gravis (2021-2030) ($MN)
• Table 5 Global Myasthenia Gravis Disease Treatment Market Outlook, By Transient Neonatal Myasthenia Gravis (2021-2030) ($MN)
• Table 6 Global Myasthenia Gravis Disease Treatment Market Outlook, By Other Types (2021-2030) ($MN)
• Table 7 Global Myasthenia Gravis Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 8 Global Myasthenia Gravis Disease Treatment Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
• Table 9 Global Myasthenia Gravis Disease Treatment Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
• Table 10 Global Myasthenia Gravis Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
• Table 11 Global Myasthenia Gravis Disease Treatment Market Outlook, By Immunosuppressants (2021-2030) ($MN)
• Table 12 Global Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Immunoglobulins (2021-2030) ($MN)
• Table 13 Global Myasthenia Gravis Disease Treatment Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 14 Global Myasthenia Gravis Disease Treatment Market Outlook, By Treatment Modality (2021-2030) ($MN)
• Table 15 Global Myasthenia Gravis Disease Treatment Market Outlook, By Surgery (2021-2030) ($MN)
• Table 16 Global Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Therapy (2021-2030) ($MN)
• Table 17 Global Myasthenia Gravis Disease Treatment Market Outlook, By Other Treatment Modalities (2021-2030) ($MN)
• Table 18 Global Myasthenia Gravis Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 19 Global Myasthenia Gravis Disease Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 20 Global Myasthenia Gravis Disease Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 21 Global Myasthenia Gravis Disease Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 22 Global Myasthenia Gravis Disease Treatment Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 23 North America Myasthenia Gravis Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 24 North America Myasthenia Gravis Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 25 North America Myasthenia Gravis Disease Treatment Market Outlook, By Generalized Myasthenia Gravis (2021-2030) ($MN)
• Table 26 North America Myasthenia Gravis Disease Treatment Market Outlook, By Ocular Myasthenia Gravis (2021-2030) ($MN)
• Table 27 North America Myasthenia Gravis Disease Treatment Market Outlook, By Transient Neonatal Myasthenia Gravis (2021-2030) ($MN)
• Table 28 North America Myasthenia Gravis Disease Treatment Market Outlook, By Other Types (2021-2030) ($MN)
• Table 29 North America Myasthenia Gravis Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 30 North America Myasthenia Gravis Disease Treatment Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
• Table 31 North America Myasthenia Gravis Disease Treatment Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
• Table 32 North America Myasthenia Gravis Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
• Table 33 North America Myasthenia Gravis Disease Treatment Market Outlook, By Immunosuppressants (2021-2030) ($MN)
• Table 34 North America Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Immunoglobulins (2021-2030) ($MN)
• Table 35 North America Myasthenia Gravis Disease Treatment Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 36 North America Myasthenia Gravis Disease Treatment Market Outlook, By Treatment Modality (2021-2030) ($MN)
• Table 37 North America Myasthenia Gravis Disease Treatment Market Outlook, By Surgery (2021-2030) ($MN)
• Table 38 North America Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Therapy (2021-2030) ($MN)
• Table 39 North America Myasthenia Gravis Disease Treatment Market Outlook, By Other Treatment Modalities (2021-2030) ($MN)
• Table 40 North America Myasthenia Gravis Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 41 North America Myasthenia Gravis Disease Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 42 North America Myasthenia Gravis Disease Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 43 North America Myasthenia Gravis Disease Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 44 North America Myasthenia Gravis Disease Treatment Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 45 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 46 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 47 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Generalized Myasthenia Gravis (2021-2030) ($MN)
• Table 48 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Ocular Myasthenia Gravis (2021-2030) ($MN)
• Table 49 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Transient Neonatal Myasthenia Gravis (2021-2030) ($MN)
• Table 50 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Other Types (2021-2030) ($MN)
• Table 51 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 52 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
• Table 53 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
• Table 54 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
• Table 55 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Immunosuppressants (2021-2030) ($MN)
• Table 56 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Immunoglobulins (2021-2030) ($MN)
• Table 57 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 58 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Treatment Modality (2021-2030) ($MN)
• Table 59 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Surgery (2021-2030) ($MN)
• Table 60 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Therapy (2021-2030) ($MN)
• Table 61 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Other Treatment Modalities (2021-2030) ($MN)
• Table 62 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 63 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 64 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 65 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 66 Europe Myasthenia Gravis Disease Treatment Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 67 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 68 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 69 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Generalized Myasthenia Gravis (2021-2030) ($MN)
• Table 70 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Ocular Myasthenia Gravis (2021-2030) ($MN)
• Table 71 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Transient Neonatal Myasthenia Gravis (2021-2030) ($MN)
• Table 72 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Other Types (2021-2030) ($MN)
• Table 73 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 74 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
• Table 75 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
• Table 76 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
• Table 77 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Immunosuppressants (2021-2030) ($MN)
• Table 78 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Immunoglobulins (2021-2030) ($MN)
• Table 79 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 80 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Treatment Modality (2021-2030) ($MN)
• Table 81 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Surgery (2021-2030) ($MN)
• Table 82 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Therapy (2021-2030) ($MN)
• Table 83 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Other Treatment Modalities (2021-2030) ($MN)
• Table 84 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 85 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 86 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 87 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 88 Asia Pacific Myasthenia Gravis Disease Treatment Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 89 South America Myasthenia Gravis Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 90 South America Myasthenia Gravis Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 91 South America Myasthenia Gravis Disease Treatment Market Outlook, By Generalized Myasthenia Gravis (2021-2030) ($MN)
• Table 92 South America Myasthenia Gravis Disease Treatment Market Outlook, By Ocular Myasthenia Gravis (2021-2030) ($MN)
• Table 93 South America Myasthenia Gravis Disease Treatment Market Outlook, By Transient Neonatal Myasthenia Gravis (2021-2030) ($MN)
• Table 94 South America Myasthenia Gravis Disease Treatment Market Outlook, By Other Types (2021-2030) ($MN)
• Table 95 South America Myasthenia Gravis Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 96 South America Myasthenia Gravis Disease Treatment Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
• Table 97 South America Myasthenia Gravis Disease Treatment Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
• Table 98 South America Myasthenia Gravis Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
• Table 99 South America Myasthenia Gravis Disease Treatment Market Outlook, By Immunosuppressants (2021-2030) ($MN)
• Table 100 South America Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Immunoglobulins (2021-2030) ($MN)
• Table 101 South America Myasthenia Gravis Disease Treatment Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 102 South America Myasthenia Gravis Disease Treatment Market Outlook, By Treatment Modality (2021-2030) ($MN)
• Table 103 South America Myasthenia Gravis Disease Treatment Market Outlook, By Surgery (2021-2030) ($MN)
• Table 104 South America Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Therapy (2021-2030) ($MN)
• Table 105 South America Myasthenia Gravis Disease Treatment Market Outlook, By Other Treatment Modalities (2021-2030) ($MN)
• Table 106 South America Myasthenia Gravis Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 107 South America Myasthenia Gravis Disease Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 108 South America Myasthenia Gravis Disease Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 109 South America Myasthenia Gravis Disease Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 110 South America Myasthenia Gravis Disease Treatment Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 111 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 112 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 113 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Generalized Myasthenia Gravis (2021-2030) ($MN)
• Table 114 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Ocular Myasthenia Gravis (2021-2030) ($MN)
• Table 115 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Transient Neonatal Myasthenia Gravis (2021-2030) ($MN)
• Table 116 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Other Types (2021-2030) ($MN)
• Table 117 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 118 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
• Table 119 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
• Table 120 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
• Table 121 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Immunosuppressants (2021-2030) ($MN)
• Table 122 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Immunoglobulins (2021-2030) ($MN)
• Table 123 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 124 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Treatment Modality (2021-2030) ($MN)
• Table 125 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Surgery (2021-2030) ($MN)
• Table 126 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Intravenous Therapy (2021-2030) ($MN)
• Table 127 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Other Treatment Modalities (2021-2030) ($MN)
• Table 128 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 129 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 130 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 131 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 132 Middle East & Africa Myasthenia Gravis Disease Treatment Market Outlook, By Other Distribution Channels (2021-2030) ($MN)

According to Stratistics MRC, the Global Myasthenia Gravis Treatment Market is accounted for $2.2 billion in 2023 and is expected to reach $3.9 billion by 2030 growing at a CAGR of 8.5% during the forecast period. The Myasthenia Gravis (MG) treatment market refers to the pharmaceutical and therapeutic landscape focused on addressing Myasthenia Gravis, a chronic autoimmune neuromuscular disorder characterized by muscle weakness and fatigue. It encompasses a range of medical interventions aimed at managing symptoms, improving neuromuscular transmission, and enhancing the overall quality of life for individuals with MG.

According to the National Organization for Rare Disorders (NORD), in the U.S., around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders worldwide.

Market Dynamics:

Driver:

Drug approvals and pipeline developments

Treatment for myasthenia gravis (MG) is largely driven by pipeline advancements and drug approvals. New drug approvals provide more therapeutic options, filling gaps in the market and improving patient outcomes. A dedication to improving treatment modalities with potential advancements in drug mechanisms and increased efficacy is indicated by ongoing pipeline developments. Additionally, these developments could result in more individualized and focused treatment plans for MG patients, reducing side effects, and improving management.

Restraint:

Lack of disease-modifying therapies

Concerning the complex and multifactorial nature of autoimmune disorders, there are currently no disease-modifying therapies available for the treatment of myasthenia gravis (MG). Targeted therapy development is difficult because, unlike some other autoimmune diseases, the underlying mechanisms causing MG are not fully understood. The majority of current therapies use acetylcholinesterase inhibitors and immunosuppression to manage symptoms; they relieve symptoms but do not address the underlying cause. However, though there is still much to learn about the exact mechanisms underlying MG and the development of disease-modifying treatments, the disorder's complexity continues to be a major barrier.

Opportunity:

Combination therapies

Combination therapies provide a promising approach to treating myasthenia gravis (MG) by addressing various aspects of the disease. Acetylcholinesterase inhibitors and immunosuppressive medications, such as corticosteroids or immunomodulators, work in concert to manage MG's characteristic muscle weakness and autoimmune response. Additionally, novel biologic therapies that target particular immune pathways have the potential to be combined with conventional medical interventions. Combination therapies seek to maximize effectiveness while reducing side effects related to high dosages of individual medications by addressing different aspects of the intricate pathophysiology.

Threat:

Variability in patient response

Patients with Myasthenia Gravis have a complex autoimmune disorder, and their responses to therapies vary from person to person. Treatment outcomes vary depending on a number of factors, including comorbidities, disease severity, and genetic variations. To address this issue, precision medicine approaches are being investigated with the goal of customizing treatments based on unique patient characteristics. However, pharmaceutical companies and medical professionals continue to be concerned about the inherent variability in MG patient responses, which has an impact on the standardization and optimization of therapeutic interventions available on the market.

COVID-19 Impact:

Significant disruptions in healthcare services and supply chains have affected patient access to medications, making COVID-19 a major factor in the market for Myasthenia Gravis (MG) treatment. While telemedicine has opened up new consultation options, in-person treatments such as plasma exchange or intravenous immunoglobulin (IVIG) have encountered logistical difficulties. Furthermore, the pandemic's financial burden has affected patient affordability and healthcare budgets, which has affected the market for MG therapies. Not with standing these difficulties, ongoing research and development initiatives keep looking into novel MG treatments that address both present roadblocks and potential future market dynamics.

The cholinesterase inhibitors segment is expected to be the largest during the forecast period

The market for myasthenia gravis treatment has witnessed robust growth in the cholinesterase inhibitors segment because of the drug's effectiveness in treating the symptoms of the autoimmune neuromuscular disease. By stopping the breakdown of acetylcholine, cholinesterase inhibitors like pyridostigmine are essential in improving neuromuscular transmission and, consequently, muscle strength and function. Additionally, the market is expected to continue expanding as myasthenia gravis treatments change and more healthcare providers include cholinesterase inhibitors in all-encompassing treatment plans.

The intravenous therapy segment is expected to have the highest CAGR during the forecast period

Given its ability to quickly alleviate acute symptoms of the disease, intravenous therapy (IVT) has become a growing segment in the market for myasthenia gravis treatment. When it comes to treating Myasthenia gravis exacerbations, intravenous administration enables accurate dosage control and prompt delivery of immunosuppressive drugs like intravenous immunoglobulin (IVIG). In severe cases, this mode of therapy is especially helpful as it guarantees a prompt response in stabilizing patients. Furthermore, the convenience of in-home IVT and improvements in infusion technologies support the growth of this market segment by giving patients a more convenient and accessible treatment option, which in turn propels market expansion.

Region with largest share:

Myasthenia Gravis (MG) treatment sales have increased substantially in the Asia-Pacific region as a result of rising MG prevalence, improving healthcare facilities, and growing public awareness of the condition. New treatment options have been introduced as a result of an increase in research and development activities in the region. Government programs to improve healthcare affordability and accessibility have also been essential in promoting market expansion. Furthermore, the treatment landscape for myasthenia gravis is constantly changing, and the APAC region is a major contributor to this evolution with its growing emphasis on personalized medicine and biotechnology advancements.

Region with highest CAGR:

The European market for myasthenia gravis treatment is constantly growing as a result of new treatments being introduced, raising awareness, and improvements in medical research. The expansion of treatment options are facilitated by partnerships between pharmaceutical companies and healthcare organizations. Additionally, the region's growing patient awareness and improved healthcare infrastructure is propelling the market expansion for myasthenia gravis treatment.

Key players in the market:

Some of the key players in Myasthenia Gravis Treatment market include AbbVie Inc., Alexion Pharmaceutical Inc., Amyasthenia gravisen inc., Astellas pharma inc., Astrazeneca, Avadel Pharmaceuticals plc, Bausch Health Companies Inc., Baxter International, Inc., Bayer ag, Biogen, Bristol-myers squibb, CSL Behring, Daiichi sankyo co. Ltd., F. Hoffmann-La Roche Ltd., Gilead sciences inc., Glaxosmithkline plc., Grifols SA, Merck & co. Inc., Novartis AG, Pfizer, Inc., Sanofi, Servier laboratories, Shire plc, Takeda Pharmaceutical Company Limited, Teva pharmaceutical industries ltd. and Valeant Pharmaceuticals International, Inc.

Key Developments:

In December 2023, GSK announced that the European Commission (EC) has granted marketing authorization to its cancer drug, Jemperli (dostarlimab), for expanded use in primary advanced or recurrent endometrial cancer. The EC has now approved Jemperli in combination with carboplatin and paclitaxel as a frontline treatment for mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced/recurrent endometrial cancer in adult patients who are candidates for systemic therapy.

In December 2023, Moderna and Merck & Co said they have started a late-stage trial of their experimental personalized mRNA cancer treatment in combination with blockbuster drug Keytruda for patients with a type of lung cancer. The therapy, V940, belongs to a class of treatments called m-RNA-based individualized neoantigen therapy (INT) and is tailored for each patient to generate T-cells, a key part of the body's immune response, based on the specific mutational signature of a tumour.

Drug Classes Covered:

• Cholinesterase Inhibitors
• Monoclonal Antibodies
• Corticosteroids
• Immunosuppressants
• Intravenous Immunoglobulins
• Other Drug Classes

Treatment Modalities Covered:

• Surgery
• Intravenous Therapy
• Other Treatment Modalities

Types Covered:

• Generalized Myasthenia Gravis
• Ocular Myasthenia Gravis
• Transient Neonatal Myasthenia Gravis
• Other Types

Distribution Channels Covered:

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies
• Other Distribution Channels

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Emerging Markets
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Myasthenia Gravis Disease Treatment Market, By Type

• 5.1 Introduction
• 5.2 Generalized Myasthenia Gravis
• 5.3 Ocular Myasthenia Gravis
• 5.4 Transient Neonatal Myasthenia Gravis
• 5.5 Other Types

6 Global Myasthenia Gravis Disease Treatment Market, By Drug Class

• 6.1 Introduction
• 6.2 Cholinesterase Inhibitors
• 6.3 Monoclonal Antibodies
• 6.4 Corticosteroids
• 6.5 Immunosuppressants
• 6.6 Intravenous Immunoglobulins
• 6.7 Other Drug Classes

7 Global Myasthenia Gravis Disease Treatment Market, By Treatment Modality

• 7.1 Introduction
• 7.2 Surgery
• 7.3 Intravenous Therapy
• 7.4 Other Treatment Modalities

8 Global Myasthenia Gravis Disease Treatment Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Online Pharmacies
• 8.3 Hospital Pharmacies
• 8.4 Retail Pharmacies
• 8.5 Other Distribution Channels

9 Global Myasthenia Gravis Disease Treatment Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Drug Class Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 AbbVie Inc.
• 11.2 Alexion Pharmaceutical Inc.
• 11.3 Amyasthenia gravisen inc.
• 11.4 Astellas pharma inc.
• 11.5 Astrazeneca
• 11.6 Avadel Pharmaceuticals plc
• 11.7 Bausch Health Companies Inc.
• 11.8 Baxter International, Inc.
• 11.9 Bayer ag
• 11.10 Biogen
• 11.11 Bristol-myers squibb
• 11.12 CSL Behring
• 11.13 Daiichi sankyo co. Ltd.
• 11.14 F. Hoffmann-La Roche Ltd.
• 11.15 Gilead sciences inc.
• 11.16 Glaxosmithkline plc.
• 11.17 Grifols SA
• 11.18 Merck & co. Inc.
• 11.19 Novartis AG
• 11.20 Pfizer, Inc.
• 11.21 Sanofi
• 11.22 Servier laboratories
• 11.23 Shire plc
• 11.24 Takeda Pharmaceutical Company Limited
• 11.25 Teva pharmaceutical industries ltd.
• 11.26 Valeant Pharmaceuticals International, Inc.